Randomized trial · people
LL-37 taken by mouth shortened time to negative COVID-19 RNA test
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This is a randomized human trial of an oral LL-37 product in which early treatment of hospitalized Omicron patients was linked to faster clearance of virus RNA without severe side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 238
- Published
- 2023
- Journal
- J Med Virol
What they tested
Researchers tested whether Oral LL-37, a recombinant Lactococcus lactis product taken by mouth, could speed clearance of an Omicron subvariant of SARS-CoV-2 and whether it was safe.
How the study was done
An open-label, randomized, placebo-controlled trial at a single center in 238 adults hospitalized with COVID-19. Open-label means patients and doctors knew who got which treatment. The main outcomes were negative conversion time, how long until tests no longer found the virus's RNA, and side effects.

What they found
When started by day 6 after the case was confirmed, Oral LL-37 shortened negative conversion time to 9.80 ± 2.67 versus 14.04 ± 5.89 with placebo (p < 0.01). Among people on Oral LL-37, starting within 6 days gave an adjusted hazard ratio for a negative test of 6.276 (95% CI 3.631-10.848) compared with starting later. Starting within 6 days also beat placebo, with a hazard ratio of 2.427 (95% CI 1.239-4.751). No severe side effects were seen during the hospital stay or follow-up.
What it doesn’t show
Patients and staff knew who got which treatment, and the trial ran at a single hospital in inpatients with one Omicron subvariant. It measured how fast virus RNA cleared and safety, not other outcomes such as symptoms.
The paper
Zhao et al. Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. J Med Virol. 2023.
The compound
More studies on LL-37
- LL-37 cream: bigger granulation gains in diabetic foot ulcersRandomized trial · people · 2023
- LL-37: no healing gain over placebo for venous leg ulcers overallRandomized trial · people · 2021
- LL-37 blood levels highest in adults with lung tuberculosisObservational study · people · 2017
- LL-37 drove IL-1β and IL-18 release from human and murine macrophagesCell study · human and murine macrophages · 2013
- LL-37 raised TLR9 and interferon output in human skin cellsCell study · normal human keratinocytes · 2012
- Every study on LL-37
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.